Statins in the primary prevention of cardiovascular events and mortality in Switzerland

Languages

Service navigation

Search

Contact information

Statins in the primary prevention of cardiovascular events and mortality in Switzerland

The Health Technology Assessment (HTA) report on statins for the primary prevention of cardiovascular events and mortality in Switzerland. This is done on the basis of the identified number and quality of the primary literature. Based on the scoping report, the HTA report examines the efficacy, safety, cost-effectiveness and budgetary impact of statin therapy in adults without established cardiovascular disease at low, moderate or (very) high cardiovascular risk compared to no treatment and/or lifestyle adjustment.

Dokumente

HTA report (PDF, 3 MB, 04.06.2021)

Stakeholder feedback on the HTA report (PDF, 530 kB, 04.06.2021)

Scoping report (PDF, 1 MB, 21.04.2020)

Stakeholder feedback on the scoping report (PDF, 312 kB, 21.04.2020)

< back to HTA projects

Last modification 04.06.2021

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/statine.html